Association between CCC and TA and incidence rate of treatment with ASMs
| Category | Variable | Beta | SE | IRR (95% CI)* | P value |
| TA | |||||
| Tracheostomy | −1.25 | 0.49 | 0.29 (0.11 to 0.75) | 0.011 | |
| Evacuation tube | 0.87 | 0.34 | 2.39 (1.22 to 4.67) | 0.011 | |
| Gastrostomy | 0.83 | 0.12 | 2.28 (1.80 to 2.91) | <0.001 | |
| Renal support | 0.18 | 0.34 | 1.20 (0.62 to 2.33) | 0.596 | |
| CCC | |||||
| Cardiovascular | −0.11 | 0.15 | 0.90 (0.66 to 1.21) | 0.467 | |
| Metabolic | −0.62 | 0.18 | 0.54 (0.38 to 0.76) | <0.001 | |
| Neonatal | 0.67 | 0.16 | 1.95 (1.42 to 2.68) | <0.001 | |
| Gastrointestinal | −0.25 | 0.22 | 0.78 (0.50 to 1.20) | 0.255 | |
| Haemat/immunol | 0.15 | 0.21 | 1.16 (0.77 to 1.74) | 0.472 | |
| Respiratory | 0.27 | 0.20 | 1.31 (0.89 to 1.92) | 0.172 | |
| Malignancy | −1.06 | 0.22 | 0.35 (0.23 to 0.53) | <0.001 | |
| Renal/uologic | 0.01 | 0.22 | 1.01 (0.66 to 1.54) | 0.981 | |
| Genetic/congenital | 0.58 | 0.14 | 1.78 (1.37 to 2.33) | <0.001 |
*Adjusted for age and gender.
ASM, acid-suppressing medication; CCC, complex, chronic conditions; IRR, incidence rate ratio; TA, technology assistance.